Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rheumatoid Arthritis
Biotech
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
Four of the five cancer assets have been discontinued entirely, and the company is currently determining next steps for the arthritis candidate.
Darren Incorvaia
May 7, 2026 11:15am
AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial
Apr 29, 2026 8:38am
Lilly reneges on remainder of Rigel RIPK1 deal
Apr 22, 2026 3:00pm
Lynk targets the JAK pot with phase 3 rheumatoid arthritis win
Jan 12, 2026 8:45am
British biotech elevates with $70M and midstage arthritis asset
Oct 21, 2025 7:01pm
SetPoint nets $140M following FDA neuromod approval in RA
Aug 11, 2025 11:30am
